These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 3496394

  • 21. Systemic induction of cells mediating antibody-dependent cellular cytotoxicity following administration of interleukin 2.
    Eisenthal A, Rosenberg SA.
    Cancer Res; 1989 Dec 15; 49(24 Pt 1):6953-9. PubMed ID: 2573425
    [Abstract] [Full Text] [Related]

  • 22. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
    Hooijberg E, van den Berk PC, Sein JJ, Wijdenes J, Hart AA, de Boer RW, Melief CJ, Hekman A.
    Cancer Res; 1995 Feb 15; 55(4):840-6. PubMed ID: 7531616
    [Abstract] [Full Text] [Related]

  • 23. Synergistic antitumor activity with IFN and monoclonal anti-idiotype for murine B cell lymphoma. Mechanism of action.
    Basham TY, Race ER, Campbell MJ, Reid TR, Levy R, Merigan TC.
    J Immunol; 1988 Oct 15; 141(8):2855-60. PubMed ID: 2971732
    [Abstract] [Full Text] [Related]

  • 24. Antibody-dependent, cell-mediated cytotoxicity by an anti-class II murine monoclonal antibody: effects of recombinant interleukin 2 on human effector cell lysis of human B-cell tumors.
    Biddle WC, Pancook J, Goldrosen M, Han T, Foon KA, Vaickus L.
    Cancer Res; 1990 May 15; 50(10):2991-6. PubMed ID: 2334902
    [Abstract] [Full Text] [Related]

  • 25. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia.
    Gregg EO, Gregg IC, Green I.
    Cancer Res; 1987 Feb 01; 47(3):723-9. PubMed ID: 3492265
    [Abstract] [Full Text] [Related]

  • 26. Synergistic antitumor effects of BCG and monoclonal antibodies capable of inducing antibody-dependent cell-mediated cytotoxicity.
    Komuta K, Kawase I, Ogura T, Masuno T, Yokota S, Hosoe S, Ikeda T, Shirasaka T, Kishimoto S.
    Jpn J Cancer Res; 1987 Feb 01; 78(2):185-92. PubMed ID: 3104261
    [Abstract] [Full Text] [Related]

  • 27. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma.
    Munn DH, Cheung NK.
    Cancer Res; 1987 Dec 15; 47(24 Pt 1):6600-5. PubMed ID: 3499978
    [Abstract] [Full Text] [Related]

  • 28. Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.
    Eisenthal A, Cameron RB, Uppenkamp I, Rosenberg SA.
    Cancer Res; 1988 Dec 15; 48(24 Pt 1):7140-5. PubMed ID: 3263900
    [Abstract] [Full Text] [Related]

  • 29. Unusually efficient tumor cell lysis by human effectors of antibody-dependent cellular cytotoxicity mediated by monoclonal antibodies.
    Christiaansen JE, Sears DW.
    Cancer Res; 1984 Sep 15; 44(9):3712-8. PubMed ID: 6744288
    [Abstract] [Full Text] [Related]

  • 30. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
    Lopes de Menezes DE, Denis-Mize K, Tang Y, Ye H, Kunich JC, Garrett EN, Peng J, Cousens LS, Gelb AB, Heise C, Wilson SE, Jallal B, Aukerman SL.
    J Immunother; 2007 Jan 15; 30(1):64-74. PubMed ID: 17198084
    [Abstract] [Full Text] [Related]

  • 31. Monoclonal antibody to a human salivary gland adenocarcinoma cell line: augmentation of antibody-dependent cell-mediated cytotoxicity activity by streptococcal preparation OK-432 in human salivary gland adenocarcinoma-bearing nude mice given the antibody.
    Kaji R, Yoshida H, Yanagawa T, Sato M.
    J Biol Response Mod; 1989 Oct 15; 8(5):488-500. PubMed ID: 2552025
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The use of a monoclonal anti-idiotype antibody to study the biology of a human B cell lymphoma.
    Hatzubai A, Maloney DG, Levy R.
    J Immunol; 1981 Jun 15; 126(6):2397-402. PubMed ID: 6785351
    [Abstract] [Full Text] [Related]

  • 34. [Interleukin-2 improves the antitumor activity of Rituximab in patients with B-cell lymphoma in vitro].
    Zhang WX, Guo J, Lin BH, Meng SN, Wang XP, Xie Y, Zheng W, Zhang YT, Zhu J.
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jan 15; 28(1):41-4. PubMed ID: 17649726
    [Abstract] [Full Text] [Related]

  • 35. Host reactivity against clonable tumor cells and the total tumor cell population, studied in a syngeneic murine lymphoma system.
    Gjedde SB.
    Acta Pathol Microbiol Immunol Scand C; 1983 Apr 15; 91(2):101-8. PubMed ID: 6349250
    [Abstract] [Full Text] [Related]

  • 36. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K, Varalakshmi C, Khar A.
    Cytokines Cell Mol Ther; 1997 Mar 15; 3(1):51-8. PubMed ID: 9287244
    [Abstract] [Full Text] [Related]

  • 37. Two distinct mechanisms of antitumor activity mediated by the combination of interleukin 2 and monoclonal antibodies.
    Vuist WM, van Buitenen F, Hekman A, Melief CJ.
    Cancer Res; 1990 Sep 15; 50(18):5767-72. PubMed ID: 1697500
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
    Drebin JA, Link VC, Greene MI.
    Oncogene; 1988 Apr 15; 2(4):387-94. PubMed ID: 2896329
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.